Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November
November 06, 2018 16:01 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals to Present Data Characterizing Significant Unmet Need in Enteric Hyperoxaluria at ASN Kidney Week 2018
October 25, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
– Highlights Additional Poster Presentation on the Design of URIROX-1, Ongoing Phase 3 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria – NEWTON, Mass., Oct. 25, 2018 (GLOBE...
Allena Pharmaceuticals Presents Preclinical Data Demonstrating Normalized Urine Uric Acid Excretion and Plasma Urate Reduction Following Treatment with ALLN-346
October 22, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
Data Presented in Poster Session at 2018 ACR/ARHP Annual Meeting NEWTON, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company...
Allena Pharmaceuticals Highlights Ongoing Efforts to Address Rare and Severe Metabolic Disorders Affecting the Kidney with Presentations at Upcoming Medical Meetings
October 18, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in October
September 25, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
August 07, 2018 16:01 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
August 07, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
- Enrolling Global Phase 3 URIROX-1™ Trial; Plan to Initiate URIROX-2™ in 2H18 - - Treated First Patients in Phase 2 Basket Study of Reloxiliase (ALLN-177) for Primary Hyperoxaluria or Enteric...
Allena Pharmaceuticals Announces First Patients Treated in Phase 2 Basket Study of ALLN-177 in Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Advanced Chronic Kidney Disease
July 23, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
June 19, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- ALLN-346, a Novel, Engineered, Urate Oxidase, Demonstrates Robust Reduction of Plasma and Urine Uric Acid After Oral Administration in an Animal Model of Hyperuricemia -- -- Data Supports...
Allena Pharmaceuticals Appoints Andrew A. F. Hack, M.D., Ph.D., to its Board of Directors
June 11, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...